BREAKING NEWS: HGS rejects GSK $2.60 billion takeover bid

Article Date: 19/04/2012 10:03
BREAKING NEWS: HGS rejects GSK $2.60 billion takeover bid

Vacancy Search

Quick job search

Advanced Search

Latest News

Vernalis stock gains on FDA nod for cough/cold drug

Vernalis stock gains on FDA nod for cough/cold drug

Hep C drugs help double Gilead's Q1 earnings

Hep C drugs help double Gilead's Q1 earnings

Report finds 'major failings' in NHS dermatology services

Report finds 'major failings' in NHS dermatology services

Breo’s watershed moment unlikely to rescue Glaxo

US development of LABA/steroid combinations for asthma virtually stopped with the FDA’s introduction of a stringent safety clampdown in 2010, so yesterday’s approval of GlaxoSmithKline’s...

Upcoming events: Survival data from Glaxo's Breo and Otonomy's move in Ménière’s

Welcome to your weekly digest of approaching regulatory and clinical readouts. With US approval of Breo Ellipta in adults with asthma in the bag, GlaxoSmithKline is now gearing up for an...

FDA clears GSK asthma inhaler for adults, not children

FDA clears GSK asthma inhaler for adults, not children

First-quarter earnings growth for Teva, Sanofi, Shire

First-quarter earnings growth for Teva, Sanofi, Shire

Gene therapy investors should keep eye out for ophthalmic data

Results from two studies of gene therapies in ophthalmic conditions due in the next few months could be critical to improving fragile investor confidence in this novel therapeutic approach....

FDA will Biogen/AbbVie's once-monthly MS shot

FDA will Biogen/AbbVie's once-monthly MS shot

Perrigo rejects Mylan's higher bid

Perrigo rejects Mylan's higher bid
more news